Rani Therapeutics Holdings (RANI) Total Liabilities (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Total Liabilities of $16.3 million for Q1 2026, down 44.57% year-over-year from $29.5 million in Q1 2025, and down 4.52% quarter-over-quarter from $17.1 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Total Liabilities (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Total Liabilities history runs 7 years deep, the most recent figure standing at $16.3 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 44.57% year-over-year to $16.3 million; the TTM figure through Mar 2026 stood at $16.3 million (down 44.57% YoY), while the FY2025 annual figure was $17.1 million, down 48.38% from the prior year.
- Total Liabilities for Q1 2026 stood at $16.3 million, down from $17.1 million in the prior quarter.
- The five-year high for Total Liabilities was $39.0 million in Q1 2024, with the low at $4.7 million in Q1 2022.
- The 5-year median for Total Liabilities is $32.5 million (2023), against an average of $27.3 million.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities soared 1188.75% in 2022, then slumped 48.38% in 2025.
- Rani Therapeutics Holdings' Total Liabilities stood at $34.0 million in 2022, then retreated by 4.56% to $32.5 million in 2023, then advanced by 2.06% to $33.1 million in 2024, then plunged by 48.38% to $17.1 million in 2025, then slipped by 4.52% to $16.3 million in 2026.
- Business Quant data shows RANI's Total Liabilities at $16.3 million in Q1 2026, $17.1 million in Q4 2025, and $22.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 10.03 Bn |
| 10 | Rani Therapeutics Holdings | 166.39 Mn | 166.39 Mn | - | 12.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.86 Mn |
| Mar 31, 2026 | 16.34 Mn |
| Dec 31, 2025 | 17.11 Mn |
| Sep 30, 2025 | 22.11 Mn |
| Jun 30, 2025 | 26.05 Mn |
| Mar 31, 2025 | 29.47 Mn |
| Dec 31, 2024 | 33.14 Mn |
| Sep 30, 2024 | 37.77 Mn |
| Jun 30, 2024 | 38.18 Mn |
| Mar 31, 2024 | 38.98 Mn |
| Dec 31, 2023 | 32.47 Mn |
| Sep 30, 2023 | 35.62 Mn |
| Jun 30, 2023 | 35.34 Mn |
| Mar 31, 2023 | 34.86 Mn |
| Dec 31, 2022 | 34.02 Mn |
| Sep 30, 2022 | 21.60 Mn |
| Jun 30, 2022 | 5.69 Mn |
| Mar 31, 2022 | 4.67 Mn |
| Dec 31, 2021 | 2.64 Mn |
| Sep 30, 2021 | 5.25 Mn |